RCC4 plus vector alone

RCC4 plus vector alone is mainly used to study the tumour suppressor gene product function - von Hippel-Lindau tumour suppressor gene. It is also used in cell responses to hypoxia.

• RCC4 plus vector alone has been used in study involving the effect of in vitro ischemia on canonical hypoxic HIF-1α (Hypoxia Inducible Factor α) stabilization.
• It has been used in the study involving CMA (chaperone-mediated autophagy)-mediated degradation of HIF1α in the lysosome.
• It has also been used to study lipodepsipeptide MDN-0066-mediated inhibition of VHL/HIF (Von Hippel-Lindau/hypoxia inducible factor) pathway.

Renal cell carcinoma cell line RCC4 stably transfected with an empty expression vector, pcDNA3, conferring neomycin resistance.

Renal cell carcinoma cell line RCC4 stably transfected with an empty expression vector, pcDNA3, conferring neomycin resistance. This cell line is VHL-deficient i.e. the von Hippel-Lindau tumour suppressor gene product is not expressed. These cells are tumourigenic.

STR-PCR Data: Amelogenin: X
CSF1PO: 10,12
D13S317: 12
D16S539: 11
D5S818: 12
D7S820: 8.2
THO1: 9.3
TPOX: 11
vWA: 16

DMEM + 10% FBS + 2 mM Glutamine + G418 0.5mg/ml

Split sub-confluent cultures (70-80%) 1:4 to 1:8 i.e. seeding at 1-3 x 10,000 cells/cm² using 0.25% Trypsin/EDTA; 5% CO₂; 37°C.

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to culturecollections@ukhsa.gov.uk.